Article Versions Notes

Wang L-C, Lin T-C, Yeh Y-C, Ho H-L, Tsai C-C, Chou T-Y. Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents. Current Oncology. 2021; 28(1):918-927. https://doi.org/10.3390/curroncol28010090

Wang, Lei-Chi, Tai-Chi Lin, Yi-Chen Yeh, Hsiang-Ling Ho, Chieh-Chih Tsai, and Teh-Ying Chou. 2021. "Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents" Current Oncology 28, no. 1: 918-927. https://doi.org/10.3390/curroncol28010090

Wang, L.-C., Lin, T.-C., Yeh, Y.-C., Ho, H.-L., Tsai, C.-C., & Chou, T.-Y. (2021). Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents. Current Oncology, 28(1), 918-927. https://doi.org/10.3390/curroncol28010090